Literature DB >> 8233745

Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants.

P R Paradiso1, D A Hogerman, D V Madore, H Keyserling, J King, K S Reisinger, M M Blatter, E Rothstein, H H Bernstein, J Hackell.   

Abstract

OBJECTIVE: To study the safety and immunogenicity of a combined diphtheria-tetanus-pertussis (DTP)-Haemophilus influenzae type b (HbOC) vaccine (TETRAMUNE) in infants as young as 2 months of age as compared to separate administration of DTP and HbOC.
METHODS: Two-month-old infants were randomized to receive three doses 2 months apart of either DTP-HbOC as a single 0.5-mL injection or to receive 0.5 mL of DTP and HbOC concurrently in separate legs. Local and systemic adverse reactions were monitored within 72 hours of each immunization, and immunogenicity of each of the four vaccine components was measured.
RESULTS: The incidence of both local and systemic adverse events following the tetravalent vaccine was similar to the incidence following separate vaccine administration. After three doses of vaccine, the response to each of the vaccine components was higher in the combined vaccine when compared to separate administration. In the case of the Haemophilus influenzae type b component, this enhancement was also seen after two doses. The response to the combined vaccine was consistent among the three lots tested as was the enhancement over separate administration.
CONCLUSIONS: The DTP-HbOC vaccine was safe and immunogenic in young infants and was generally more immunogenic than separate vaccination with DTP and HbOC. The use of such a combined vaccine reduces the number of injections given to young infants by half and is an important step toward improving vaccine delivery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8233745

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  Supplementary statement on newly licensed Haemophilus influenzae type B (Hib) conjugate vaccines in combination with other vaccines recommended for infants.

Authors: 
Journal:  CMAJ       Date:  1995-02-15       Impact factor: 8.262

2.  Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Authors:  Susanna Esposito; Susan Tansey; Allison Thompson; Ahmad Razmpour; John Liang; Thomas R Jones; Giuseppe Ferrera; Alessandro Maida; Gianni Bona; Caterina Sabatini; Lorenza Pugni; Emilio A Emini; William C Gruber; Daniel A Scott; Nicola Principi
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

Review 3.  Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom.

Authors:  Dominic F Kelly; E Richard Moxon; Ly-Mee Yu; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

Review 5.  Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine.

Authors:  Ingrid L Scully; Paul A Liberator; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Front Immunol       Date:  2014-03-24       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.